Skip to main content

Advertisement

Fig. 2 | Breast Cancer Research

Fig. 2

From: Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells

Fig. 2

a MDAMB231, b MDAMB453, and c MDAMB468 cells were treated with 250 nM prexasertib for 24 h and co-treated with or without 10 μM MG132 for the last 16 h. Protein expression was evaluated by western blot. d MDAMB231, e MDAMB453, and f MDAMB468 cells were treated with 250 nM prexasertib and co-treated with or without 1 μM epoxomicin for 24 h with protein expression analyzed by western blot. g Densitometry analysis for BRCA1 and RAD51 expression in all three TNBC cell lines are represented in histogram with standard deviation as error bars. h RT-qPCR analysis of prexasertib-treated TNBC cells compared with vehicle (DMSO). Fold difference with standard deviation is represented as histogram (***p < 0.001)

Back to article page